Cogent Biosciences Inc. Common Stock (COGT)

About COGT

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations i…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

258

Website

www.cogentbio.com/

Fundamentals

1-day range

$34.53$36.85

Market cap

$6.64B

P/E (trailing)

—

P/E (forward)

-31.28

EPS (trailing)

$-2.51

Dividend yield

—

Beta

0.31

Avg. volume

2.41M

Dividend pay date

November 9, 2020

Forecasts

11 analyst ratings

Cogent Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $6.64BP/E —
  $11.6$43.73
• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $6.38BP/E —
  $63.23$130
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• LGND

  Ligand Pharmaceuticals Incorporated Common Stock

  $280

  ▼ 1.59%
  Market cap $5.85BP/E 38.07
  $158.4$326.63
• DNTH

  Dianthus Therapeutics Inc. Common Stock

  $105.72

  ▼ 5.22%
  Market cap $5.80BP/E —
  $22.81$117.88
• KNSA

  Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

  $78.1

  ▼ 2.13%
  Market cap $5.73BP/E 75.29
  $33.25$82.94

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
  SeekingAlpha · 8/27/2026
• Prelude Therapeutics: A Prognosis After Year-Long Rally
  SeekingAlpha · 8/23/2026
• Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
  Benzinga · 8/17/2026
• Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52
  Benzinga · 8/12/2026
• Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock
  Benzinga · 8/10/2026
• Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate
  Benzinga · 8/10/2026
• If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
  Benzinga · 8/7/2026

• Ferrante Karen Jean · July 1, 2026 · Grant

  627
• Shegog Todd · June 9, 2026 · Grant

  17.9K
• Ros Matthew · June 9, 2026 · Grant

  17.9K
• Harwin Peter Evan · June 9, 2026 · Grant

  17.9K
• CAIN CHRISTOPHER W. · June 9, 2026 · Grant

  17.9K
• Ferrante Karen Jean · June 9, 2026 · Grant

  17.9K
• Arlene Morris · June 9, 2026 · Grant

  17.9K
• Andrew R. Robbins · May 19, 2026 · Gift

  160.0K
• Ferrante Karen Jean · April 1, 2026 · Grant

  686
• Fairmount Funds Management LLC · March 31, 2026 · Conversion

  28.0K
• Fairmount Funds Management LLC · March 31, 2026 · Sale

  7.00M @ $34.66
• Fairmount Funds Management LLC · March 31, 2026 · Conversion

  7.00M

Institutional Ownership

March 31, 2026

Total shares held

178.49M

Total value held

$6.60B

Institutional holders

299